These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 19164244

  • 1. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice.
    Ferl GZ, Dumont RA, Hildebrandt IJ, Armijo A, Haubner R, Reischl G, Su H, Weber WA, Huang SC.
    J Nucl Med; 2009 Feb; 50(2):250-8. PubMed ID: 19164244
    [Abstract] [Full Text] [Related]

  • 2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [Abstract] [Full Text] [Related]

  • 3. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X.
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [Abstract] [Full Text] [Related]

  • 4. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
    Cai W, Chen K, Li ZB, Gambhir SS, Chen X.
    J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
    [Abstract] [Full Text] [Related]

  • 5. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X.
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [Abstract] [Full Text] [Related]

  • 6. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles.
    Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X.
    J Nucl Med; 2008 Aug; 49(8):1371-9. PubMed ID: 18632815
    [Abstract] [Full Text] [Related]

  • 7. (64)Cu labeled AmBaSar-RGD2 for micro-PET imaging of integrin αvβ3 expression.
    Cai H, Li Z, Huang CW, Park R, Conti PS.
    Curr Radiopharm; 2011 Jan; 4(1):68-74. PubMed ID: 22191616
    [Abstract] [Full Text] [Related]

  • 8. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
    Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS.
    Bioconjug Chem; 2004 Jan; 15(1):41-9. PubMed ID: 14733582
    [Abstract] [Full Text] [Related]

  • 9. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.
    J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
    Hernandez R, Czerwinski A, Chakravarty R, Graves SA, Yang Y, England CG, Nickles RJ, Valenzuela F, Cai W.
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
    Cai H, Li Z, Huang CW, Shahinian AH, Wang H, Park R, Conti PS.
    Bioconjug Chem; 2010 Aug 18; 21(8):1417-24. PubMed ID: 20666401
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Integrin alpha v beta 3-targeted imaging of lung cancer.
    Chen X, Sievers E, Hou Y, Park R, Tohme M, Bart R, Bremner R, Bading JR, Conti PS.
    Neoplasia; 2005 Mar 18; 7(3):271-9. PubMed ID: 15799827
    [Abstract] [Full Text] [Related]

  • 19. Integrin αvβ3 as a Promising Target to Image Neoangiogenesis Using In-House Generator-Produced Positron Emitter (68)Ga-Labeled DOTA-Arginine-Glycine-Aspartic Acid (RGD) Ligand.
    Vatsa R, Bhusari P, Kumar S, Chakraborty S, Dash A, Singh G, Dhawan DK, Shukla J, Mittal BR.
    Cancer Biother Radiopharm; 2015 Jun 18; 30(5):217-24. PubMed ID: 26083951
    [Abstract] [Full Text] [Related]

  • 20. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ.
    Nucl Med Biol; 2015 Feb 18; 42(2):99-108. PubMed ID: 25459113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.